Abstract
The term “translational research” refers to investigations at the interface between the laboratory and the clinic. Laboratory research regarding the pathophysiology of peptide growth factors in breast cancer has been ongoing for more than two decades and has led to important insights regarding the pathophysiology of this malignancy. The development of novel treatment strategies based on hypotheses arising from laboratory research concerning peptide growth factors is a relatively recent and encouraging development. In this presentation, only three representative examples of translational research related to peptide growth factors in breast cancer will be reviewed. While many other important examples exist, these three cases should serve to illustrate how laboratory research is yielding concepts suitable for evaluation in clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arteaga C, Kitten L, Coronado E et al. (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in nude mice. J Clin Invest 84: 1418–1423
Carter P, Presta L, Gorman C et al. (1992) Humanization of an anti-p185-HER2 antibody for human cancer treatment. Proc Natl Acad Sci USA 89: 4285–4289
Drebin J, Link V, Greene M (1988) Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2: 387–394
Filmus J, Trent J, Pollak M, Buick R (1987) EGF receptor gene-amplified MDA-468 breast cancer cell line and its non-amplified variants’: Mol Cell Biol 7: 251–257
Furman-Haran E, Maretzek A, Goldberg I, Horowitz A, Degani H (1994) Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 54: 5511–5514
Huynh H, Pollak M (1994) Enhancement of tamoxifen-induced suppression of IGF-I gene expression and serum levels by a somatostatin analogue. Biochem Biophys Res Commun 203: 253–259
Huynh H, Tetenes E, Wallace L, Pollak M (1993) In vivo inhibition of IGF-I expression by tamoxifen Cancer Res 53: 1727–1730
Lee M, Liebow C, Kamer A, Schally AV (1991) Effects of epidermal growth factor and analogues of LHRH and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates invarious tumors. Proc Natl Acad Sci USA 88: 1656–1660
O’Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M, Lane W, Cao Y, Sage E, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315–328
Pollak M (1993) Effects of adjuvant tamoxifen therapy on growth hormone and IGFI physiology. In: Salmon S (ed) Adjuvant therapy of cancer V II. Lippincott, Philadelphia
Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R (1990) Effect of tamoxifen on IGF-I levels in stage I breast cancer patients J Natl Cancer Inst 82: 1963–1967
Pollak M, Gora P, Boyarsky A (1991) A mathematical model describing consequences of abnormally high levels of epidermal growth factor receptor on the proliferation of neoplastic cells. Cancer Invest 9: 513–520
Setyono-Han B, Henkelman M, Foekens J, Klijn G (1987) Direct inhibitory effects of somatostatin analogues on the growth of human breast cancer cells. Cancer Res 47: 156–157
Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177–182
Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV (1992) Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LHRH, an analogue of somatostatin, or a combination. Breast Cancer Res Treat 21: 181–192
Van Eijck C, Krenning E, Bootsma A, Lindemans J, Jeekel J, Reubi J, Lamberts S (1994) Somatostatin receptor scintigraphy in primary breast cancer. Lancet 343: 640–643
Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C (1994) Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on DMBA-induced rat mammary carcinomas. Cancer Res 54: 6334–6337
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Pollak, M. (1996). Peptide Growth Factors and Breast Cancer Treatment: Recent Translational Research. In: Senn, H.J., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Breast Cancer V. Recent Results in Cancer Research, vol 140. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79278-6_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-79278-6_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79280-9
Online ISBN: 978-3-642-79278-6
eBook Packages: Springer Book Archive